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HISTORY
Well over 1000 HLA-identical marrow transplantations
have been performed since the early 1980s in patients with
severe aplastic anemia [1], a disease that can result from
immunological suppression of the bone marrow. Therefore,
many transplantation centers already have considerable
experience in treating immune-mediated disorders with
high-dose therapy and allogeneic marrow transplantation.
In the last 5 to 6 years, new investigational autologous
transplantation protocols have been developed for treat-
ment of nonhematological autoimmune diseases. A number
of technological advances gave impetus to this develop-
ment, including methods of peripheral blood stem cell col-
lection and T-cell purging. Equally important, preclinical
studies of certain animal models of autoimmunity suggested
that, in addition to allogeneic transplantation, high-dose
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ABSTRACT
Since 1996, a number of investigators have carried out phase I-II studies of high-dose immunosuppression with
autologous hematopoietic stem cell transplantation (HSCT) in autoimmune diseases. Most of this activity has been
in studies of multiple sclerosis (MS), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), and juvenile idiopathic arthritis (JIA). Supported by animal models of antigen-induced autoimmu-
nity, the rationale of HSCT is to time-shift the clinical autoimmunity to an earlier period, restoring self-tolerance.
Even with the considerable experience of more than 200 transplantations since 1996, it is difficult to judge the
optimal approach. This difficulty is in part because of the multiplicity of centers and protocols and the variability in
patient eligibility and assessment, the extent of T-cell depletion, and the intensity of the preparatory regimens
used. Other than that found in RA, treatment-related mortality has been higher than expected: 17% in SSc (with
an additional 10% mortality from progressive disease), 13% in SLE, 13% in JIA, and 8% in MS. Protocol changes
to improve safety have been instituted. These changes include the avoidance of high-dose rabbit antithymocyte
serum in patients who received T-cell–depleted grafts, use of corticosteroids with granulocyte colony-stimulating
factor during stem cell mobilization and as prophylaxis for the engraftment syndrome in MS, lung radiation shield-
ing in SSc, and multiple precautions against the macrophage activation syndrome in JIA. Responses to primary and
secondary endpoints have been seen, and there is a consensus among investigators and regulatory bodies that the
time has come for randomized phase II-III studies. Each disease presents distinct difficulties: in MS, restriction of
eligibility to patients with active inflammatory disease; in SSc, formulation of cardiopulmonary eligibility criteria to
decrease risk; in SLE, judgment of whether HSCT adds any advantage to high-dose nonmyeloablative immuno-
suppressive treatment alone; and in RA, enhancement of response durability. All prospective randomized studies in
these diseases must address problems in selection of the comparison nontransplantation treatment and appropriate
stopping rules, particularly with treatment arms of unequal risk. Parallel trials in Europe and in the United States
are in the late stages of design.
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immunosuppressive therapy with autologous hematopoietic
stem cell transplantation (HSCT) support might also be an
effective treatment [2].
Influenced by these preclinical studies and anecdotal
reports of patients who underwent marrow transplantation
for hematological malignancy and were cured of autoimmune
disease, transplantation physicians and rheumatologists orga-
nized an autoimmune disease meeting in October 1995 at
Fred Hutchinson Cancer Research Center in Seattle [3]. As
interest and experience grew, A. Gratwohl and A. Tyndall
set up biennial conferences in Basel beginning in October
1996 under the sponsorship of the European Group for
Blood and Marrow Transplantation (EBMT) and the Euro-
pean League against Rheumatism (EULAR). Reports from
these Basel meetings have been published [4-6]. On alternate
years, R. Burt and R. Emmons hosted meetings in Worcester,
Massachusetts.
More than 70 centers from 20 countries have contributed
cases to the EBMT registry. In North America, transplan-
tations have been performed at 20 centers, although approxi-
mately two thirds have been carried out with common
protocols developed by either the Northwestern or the Seat-
tle groups. Early in 2001, to avoid duplication in the registries
of the cases from North America, data were transferred from
EBMT to the International Bone Marrow Transplant Reg-
istry (IBMTR).
Figure 1 shows a breakdown of transplantations by year
in the EBMT registry (data courtesy of Dr. Alan Tyndall for
EBMT). The largest number of transplantations has been
for multiple sclerosis (MS), although the number decreased
in 2000, possibly in anticipation of planned controlled trials
in MS. The number of transplantations for rheumatoid
arthritis (RA) also decreased in 2000, whereas the number
for systemic sclerosis (SSc), systemic lupus erythematosus
(SLE), and juvenile idiopathic arthritis (JIA) remained
approximately the same. Other diagnoses for which more
than 5 patients were reported to the EBMT registry include
idiopathic thrombocytopenic purpura (9 patients), poly-
myositis (7 patients), and autoimmune hemolytic anemia
(6 patients). The North American experience has been
mostly with MS and SSc; very few patients with RA or JIA
have been treated.
The data in Figure 1 are from autologous HSCT. There
have been rare syngeneic transplantations performed for
autoimmune diseases [7], but with the strong genetic inﬂu-
ence on autoimmunity, the advantage of syngeneic over autol-
ogous transplantations may be modest. Nonmyeloablative
allogeneic transplantation with mixed chimerism [8] has theo-
retical appeal because of the reduced risk of regimen-related
morbidity and mortality compared to allogeneic transplanta-
tions and the potential for a graft-versus–autoreactive
immune cell effect. Concern about risks from graft-versus-
host disease has delayed activation of allogeneic protocols, at
least until there is a better idea of the effectiveness of autolo-
gous transplantations.
This review, written in preparation for the October
2001 conference on Stem Cell Therapy in Autoimmune
Diseases, held in Los Angeles, summarizes clinical reports
and abstracts of open-label, pilot studies published up to
mid-2001.
RATIONALE OF AUTOLOGOUS HSCT IN AUTOIMMUNE
DISEASE
Introduction
Figure 2 presents a simpliﬁed time line for the develop-
ment of an autoimmune disease and progression to target-tissue
Figure 2. Time line for development of autoimmune disease. The
framed section shows 2 possible mechanisms of high-dose immunosup-
pression and hematopoietic stem cell transplantation: an anti-inﬂam-
matory effect decreasing target-tissue injury and a more durable
immunosuppressive effect restoring self-tolerance.
Figure 1. Number of autologous HSCT reported to EBMT yearly between 1996 and 2000 for MS, SSc, and SLE (left panel) and RA and JIA
(right panel). Data supplied by Alan Tyndall, MD, for EBMT.
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injury. Genetic makeup and environmental exposure play criti-
cal roles [9,10]. An individual’s susceptibility to clinical
autoimmunity depends on genetic makeup or, more speciﬁ-
cally, the balance of immune-enhancing and immune-protec-
tive genes. These genes affect cytokines, HLA expression, cos-
timulatory molecules, apoptosis pathways, antigen receptor
and signaling, regulatory cell level, immune complex clear-
ance, and other functions [9]. Whether and when a genetically
predisposed individual develops an autoimmune disease
and possibly the nature of the autoimmune disease—organ
speciﬁc or generalized—may depend on contact with envi-
ronmental agents, infectious and noninfectious. Evidence
for these still-uncharacterized environmental agents include
greater risk in temperate climates, point epidemics, and lack
of 100% concordance in monozygotic twins [11]. Moreover,
retrospective studies in patients who had migrated from
high- to low-prevalence areas suggest that there is a latent
period, ie, a delay of many years between contact with a
hypothetical environmental agent and clinical onset of the
disease. The concepts of an environmental trigger and a
latent period are important in the rationale of autologous
HSCT as treatment for autoimmune diseases. If genetic
predisposition alone is sufﬁcient for development of clinical
autoimmunity, then the predisposition for the disease
resides solely in the hematopoietic stem cells, and the best
result that can be hoped from autologous HSCT would be a
temporary anti-inflammatory effect from the high-dose
immunosuppression. In contrast, if particular environmental
exposures at critical times are important, then high-dose
immunosuppressive therapy with autologous HSCT has the
potential to “time shift” the clinical autoimmune disease line
to an earlier period, analogous to the latent period, restor-
ing self-tolerance. This rationale assumes that responses on
reexposure to even the same self-antigens will be sufﬁciently
different that clinical autoimmunity will not recur.
Animal Models of Autoimmunity and HSCT
As shown in Table 1, there are 2 types of autoimmune
disease models: (1) autoimmune-prone animals that sponta-
neously develop either generalized autoimmunity, such as the
classic model of SLE in NZB×NZW F1 mice, or organ-
speciﬁc autoimmunity, such as the model of diabetes mellitus
NOD mice and (2) antigen-induced models of autoimmune
diseases, such as adjuvant arthritis and experimental allergic
encephalomyelitis (EAE). In cases of spontaneous autoim-
mune diseases, syngeneic bone marrow transplantation early
in life has not prevented clinical or pathological autoimmu-
nity; however, allogeneic transplantations from an autoim-
mune resistant strain have prevented and in some instances,
when given early after disease onset, ameliorated the autoim-
mune manifestations [12]. These results have lead Good and
Ikehara to conclude that autoimmunity derives from
hematopoietic stem cells [13]. In contrast, studies of antigen-
induced autoimmune diseases by van Bekkum and his col-
leagues have shown a therapeutic response from syngeneic
or pseudoautologous transplantations [2]. For example,
recovery from EAE-induced paresis was more rapid in animals
treated with total body irradiation (TBI) and syngeneic trans-
plantation compared to that in untreated animals, although
allogeneic transplantations were superior in preventing spon-
taneous relapses and induced relapse from reimmunization
of myelin protein [14,23]. Timing of the transplantation is
important. For example, with EAE in SJL mice, treatment
was effective only if given early in the course of the disease,
before signiﬁcant target-tissue injury [15].
Implications of Immunological Reconstitution
The strongest rationale justifying autologous HSCT
concerns the effect of high-dose chemotherapy on T-cell
recovery. Non–T-cell immune recovery, with maturation
through the marrow rather than the thymus, is more rapid
than T-cell recovery, although full functional recovery of all
immunoglobulin (Ig) isotypes may take up to 2 years [24]. In
general, the number of CD3 cells normalizes 3 months after
high-dose chemotherapy, but reduced numbers of CD4 cells
and an inverted CD4/CD8 cell ratio persist for 12 months
along with predominance of CD45RO+ cells, deﬁciency of
naive CD45RA+ cells in thymus-deﬁcient adult patients, and
Table 1. Animal Models of Autoimmunity: Effect of Marrow Transplantation
Pathology/Disease Animal Model Transplantation
Spontaneous autoimmune disease [13]
Models of SLE
Immune complex disease
Thrombocytopenia (NZB×NZW) F1 mice Prevented and treated by allogeneic transplantation [16-20]
Coronary vascular disease BXSB mice
Glomerulonephritis (NZW×BXSB) F1 mice
Lymphoproliferative disease MRL/pr mice
Autoantibodies
Model of diabetes mellitus NOD mice Prevented by allogeneic transplantation [12,21]
Antigen-induced autoimmune disease [2]
Adjuvant arthritis Buffalo rat Treated by syngeneic and allogeneic transplantation [22]
Model of RA
Polyarthritis
Experimental allergic encephalomyelitis Buffalo rat Treated by syngeneic and allogeneic transplantation [14,23]
Model of MS SJL mice
CNS inflammation Lewis rat
Demyelination
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restriction in the T-cell repertoire [25-28]. A greater degree
of resulting immunosuppression would be anticipated in
most HSCT protocols for autoimmune diseases because of
both ex vivo depletion of T-cells in the graft by CD34+ cell
selection and antithymocyte globulin (ATG) therapy at the
time of stem cell reinfusion.
In most autoimmune diseases, the epitope of the initial
target antigen is unknown. Autoreactive T-cells, eg, to myelin
antigens, are found in normal individuals [29]. The immune
dysregulation leading to clinical loss of tolerance in autoim-
mune diseases may involve an increase in the number of
autoreactive cells through molecular mimicry of viral or other
foreign antigens, an increase in epitope spreading as shown in
Figure 2, or target-organ microenvironment changes allow-
ing optimal cytokine and other conditions for T-cell activation
[9,30-32]. Unfortunately only a few studies have monitored
autoreactive T-cells after autologous HSCT in patients. In
EAE, marrow ablative therapy and transplantation clears
encephalitogenic T-cells from the central nervous system
(CNS) within 3 weeks [33]. In a limited number of MS
patients followed after autologous HSCT, the anticipated
general suppression of peripheral blood mononuclear cell
proliferation to myelin antigens occurred after transplanta-
tion and persisted at least 20 months, but some new responses
to different myelin protein epitopes also developed as early as
8 months after transplantation [34]. The clinical signiﬁcance
of changes in autoreactive cells after transplantation is
unknown. There has been a proposal to carry out DNA
marking of stem cells in the autologous graft [35], analogous
to the approach used to determine the origin of relapsed
hematological malignancy after transplantation [36]. There
are a number of intrinsic difficulties with this approach,
including limited transduction efficiency of stem cells and
uncertainty in differentiating a physiologic from pathogenetic
autoreactive cell. However, DNA marking in patients in
whom autologous HSCT failed could theoretically make the
distinction between the transfer of pathogenetic T-cells in the
graft, an outcome that may be overcome by selectively modi-
fying the graft, and the transfer of stem cells that gave rise to
pathogenetic T-cells, an outcome that would argue strongly
for an allogeneic transplantation approach.
Autologous and Allogeneic Transplantations for
Hematological Disease in Patients with Preexisting
Autoimmunity
Because autoimmune diseases all together afflict up to
5% of the population [9], it is likely that a considerable num-
ber of patients with preexisting clinical autoimmunity have
undergone allogeneic or autologous transplantation for onco-
logic disease. The literature in this area, however, is mostly
anecdotal and sparse, especially regarding autologous trans-
plantation. In a review, Tyndall and Gratwohl (1999) have
cautioned that the tendency to report positive results may
account for the mostly favorable experiences published [37].
In a single-institution retrospective study, 11 of 909 patients
were identiﬁed who had preexisting autoimmune diagnoses
and had survived at least 3 years after allogeneic transplanta-
tion. Although no autoimmune activity posttransplantation
was reported [38], at least 7 of these patients had diagnoses
or disease stages in which progression would not be antici-
pated (eg, type 1 diabetes mellitus and treated Hashimoto’s
thyroiditis). Recently, 2 additional patients with autoim-
mune thyroiditis were reported whose autoantibodies
decreased and whose disease remitted after allogeneic mar-
row transplantation for aplastic anemia [39]; and similar to
an earlier case report [40], 3 additional MS patients from
one center had stable neurological disability after transplan-
tation (2 autologous and 1 allogeneic) for hematological
malignancy [7]. There are, however, some failures reported.
An abstract from 1998 describes an MS patient who devel-
oped new optic neuropathy 2 months after allogeneic trans-
plantation for chronic myelogenous leukemia and whose
magnetic resonance image (MRI) of the brain showed sev-
eral new lesions at 1 year [41]. There are also reports of
RA relapsing after allogeneic transplantation [42] and RA
and SLE relapsing after autologous transplantation for
oncologic disease [43]. Failure to correct coincidental
autoimmunity in autologous transplantation patients could
be attributed to a suboptimal preparatory regimen or lack of
T-cell depletion of the graft, factors that should be opti-
mized when transplantations are performed speciﬁcally for
autoimmune diseases. On the other hand, reports of autoim-
mune disease progression after allogeneic transplantation,
particularly when posttransplantation hematopoiesis is
100% donor-derived, as in a patient with relapsed RA [42],
would suggest that autoimmune-prone genetic factors in the
donor were sufﬁciently shared with the sibling recipient or
that the target-tissue microenvironment in the recipient was
so autoimmune-prone that allogeneic cells became reactive.
Development of Pathogenetic Immune Events 
after HSCT
A related consideration is induction of autoimmunity by
transplantation, the process Marmont has characterized as
“adoptive autoimmunity” [44]. Allogeneic stimulation has
been shown to reactivate EAE [45], and scleroderma-like signs
are common in chronic graft-versus-host disease [46]. More-
over, some organ-specific autoimmune diseases for which
autologous HSCT have been performed—polymyositis and
myasthenia gravis, for example—can themselves occur (albeit
uncommonly) as complications of chronic graft-versus-host
disease [47,48]. Myelitis and optic neuritis with MRI abnor-
malities of demyelination, identical to abnormalities seen in
MS, have been reported in rare instances in transplantation
patients [49]; and there have been reports of immune-medi-
ated neuropathies, some with demyelinating features sugges-
tive of chronic Guillain Barré syndrome, after transplantation
[50]. Autologous graft-versus-host disease can be induced by
cyclosporin administered early after transplantation [51], and
many of the immune-mediated complications of transplanta-
tion noted in this section have been seen in autologous as well
as allogeneic transplantation [50,52]. Therefore, it would not
be totally unexpected if in some instances a second autoim-
mune disease occurs after HSCT or if paradoxical worsening
of the original autoimmune disease occurs.
PROTOCOLS FOR AUTOLOGOUS HSCT FOR 
AUTOIMMUNE DISEASES
Eligibility
For phase I-II studies on feasibility, investigators used
selection criteria that were based on severe disease, progres-
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sive despite available therapy, but without infection or organ
damage that would preclude transplantation. Eligibility crite-
ria varied according to protocol and transplantation center. In
the United States, approval from the Food and Drug Admin-
istration (FDA) was required because most investigators
chose to use CD34+ cell selection devices. This role of the
FDA assured some uniformity in eligibility of US protocols.
For MS, the expanded disability status scale (EDSS), a
standard disability scale validated for investigational studies,
was used to determine eligibility [53]. Most protocols speci-
ﬁed EDSS of 5.0 or 5.5 to 8.0 points. At this range in the
EDSS, disability grading is based mainly on gait: EDSS 5.5,
patients can walk 100 meters but not 200 meters without
aid or rest; EDSS 6.0, patients need a cane or brace to walk
100 meters; EDSS 6.5, patients need bilateral assistance of
canes or crutches to walk 20 meters; EDSS 7.0, patients are
unable to walk more than 5 meters even with aids; EDSS 7.5,
patients are unable to take more than a few steps and may
need help with transfers; and EDSS 8.0, patients are wheel-
chair- or bed-bound. Documented advancement of 1 to
2 points on the EDSS in the 1 to 2 years prior to entry was
required in most protocols, but MRI gadolinium enhance-
ment as an indication of active disease has not generally been
required. In SSc, proposed inclusion criteria have generally
included disease duration limited to less than 3 years and dif-
fuse cutaneous involvement with a modified Rodnan skin
score (mRSS) [54] of greater than 16, together with at least
1 of the following visceral involvements: pulmonary with
active alveolitis and a forced vital capacity (FVC) of less than
80%, renal involvement with proteinuria and elevated serum
creatinine, and heart involvement with arrhythmias, car-
diomegaly, or pericardial effusion [55]. Based on the report
from the European registry [56], some investigators included
patients with CREST syndrome (calcinosis cutis, Raynaud
phenomenon, esophageal motility disorder, sclerodactyly,
and telangiectasia) who had advanced pulmonary hyperten-
sion. To date, no single study has been reported that details
specific SyS eligibility criteria. In SLE, inclusion criteria
include catastrophic antiphospholipid syndrome or failed
cyclophosphamide for glomerulonephritis (World Health
Organization class III-IV), CNS lupus, vasculitis involving
the heart or lung, or life-threatening cytopenias [57]. For
RA, inclusion criteria differed slightly among published pilot
studies, but all required a conﬁrmed diagnosis of RA based
on the American College of Rheumatology criteria and fail-
ure to respond to conventional therapy [58-61]. Current pro-
tocols also require failure of anti–tumor necrosis factor
(TNF)-receptor treatment. For JIA, eligible subjects must
have poor-prognosis disease—such as persistence of throm-
bocytosis, fever, and steroid dependency 6 months into the
disease—and have failed all conventional therapy, including
anti–TNF-receptor treatment [62].
Peripheral Blood Stem Cell Mobilization
Details have been published on stem cell mobilization
for 187 patients who underwent transplantation at 24 cen-
ters worldwide [63]. These cases include 54 in North America
and approximately 50% of the cases in the EBMT registry.
Bone marrow rather than peripheral blood stem cells have
been used in at least 60% of patients with JIA, whereas
transplants for patients with other diagnoses have been
almost exclusively peripheral blood stem cells. In Europe,
granulocyte colony-stimulating factor (G-CSF) without
cyclophosphamide has been uncommonly used for stem cell
mobilization, except for treatment of RA; whereas some
North American protocols use G-CSF alone for MS and
SSc [34,64,65]. Most protocols have used cyclophosphamide
at 4 g/m2 followed by daily G-CSF at 5 µg/kg per day until
completion of mobilization. Generally autografts contained
at least 3.0 × 106 CD34+ cells/kg, although required cell
dose varied from protocol to protocol. Some centers have
reported occasional patients for whom mobilization failed
[66]. CD34+ cell selection with the Isolex or CellPro device
has been used in the North American centers, but CD34+ cell
selection was done in only about 50% of the RA patients
and 60% of MS patients in the EBMT registry.
On the basis of animal studies and with reference to
patients who have relapsed after autologous HSCT with
unmanipulated grafts [43], van Bekkum has made a strong
argument in favor of T-cell purging [2,67]. An unmanipu-
lated peripheral blood stem cell graft generally contains 1010
T-cells, 2 logs more than the estimated number of T-cells
that survive 900-cGy radiation conditioning. A total of
106/kg T-cells (obtained by CD34+ cell selection) has been
suggested as the maximum number of reinfused T-cells in
manipulated grafts [2].
Preparatory Regimens
There has been great heterogeneity in preparatory regi-
mens used. Figure 3 gives a breakdown of the 4 most com-
monly used preparatory regimens for specific diseases
reported to the EBMT registry through 2000. BEAM was
used in approximately half the patients who underwent trans-
plantation for MS, but in only a few patients with other
autoimmune diagnoses. BEAM consists of the following:
BCNU (carmustine) 300 mg/m2 on day –6, cytosine arabi-
noside 200 mg/m2 and etoposide 200 mg/m2 from days –5 to
–2, and melphalan 140 mg/m2 on day –1 [68]. Cyclophos-
phamide alone was used most often in SSc, RA, and SLE. In
the EBMT registry, cyclophosphamide in combination with
TBI was the most frequently used preparatory regimen in
Figure 3. Preparatory regimens in transplantation cases reported to the
EBMT registry for MS, SSc, RA, SLE, and JIA. BEAM indicates BCNU,
etoposide, cytosine arabinoside, melphalan; Bu, busulfan; Cy, cyclophos-
phamide; TBI, total body irradiation. Data courtesy of Alan Tyndall,
MD, for EBMT. 
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JIA. In North America, cyclophosphamide (120 mg/kg) com-
bined with TBI has been used by both the Northwestern
(TBI, 1200 cGy) and Seattle (TBI, 800 cGy) groups for MS,
and the Seattle group has used the same regimen for SSc [64].
Some investigators have assumed that early relapses of
autoimmunity after transplantation are from residual autore-
active T-cells remaining after conditioning therapy or
autoreactive T-cells at too high a level in the graft. ATG
treatment at the time of stem cell reinfusion is intended to
deplete both reinfused T-cells and T-cells that survive condi-
tioning. ATG has been used in approximately 80% of MS
patients in the EBMT registry and is included in the Seattle
but not the Northwestern MS protocols. ATG has been used
in less than 10% of transplantations in RA cases, in less than
50% of transplantations in SSc cases, and in two thirds of
transplantations in SLE cases in the EBMT registry. In
North America, ATG is included in the multicenter SSc pro-
tocol [64], and ATG was included in the Northwestern phase
I SLE trial [57]. Arguments, however, against such extensive
T-cell purging have also been made. Reported by S. Millikan
and coworkers at the 2000 Basel meeting was an Australian
comparison trial showing that CD34+ cell selection did not
improve the duration of remission after autologous HSCT in
RA (described in [6]). Whether these ﬁndings are relevant to
other autoimmune diseases remains uncertain. Clearly, if the
goal of therapy is primarily anti-inﬂammatory, then T-cell
depletion may be less important. Concerns have also been
expressed in terms of the acute toxicity of ATG in patients so
ill at the time of their conditioning and the long-term risks
of infection and lymphoproliferative disease from the marked
immunosuppression after coupling CD34+ cell selection with
ATG treatment. Fatal lymphoproliferative disease, attributed
to the potent immunosuppressive properties of rabbit ATG
given in conjunction with intensive TBI-based immunosup-
pressive regimens, has been seen in 2 patients receiving
HSCT for autoimmune disease [64,65].
Unfortunately, there is very little comparative data on the
immunosuppressive effects of different preparatory regimens
or different doses of immunosuppressive agents on autoreac-
tive T-cells. Brodsky has shown that cyclophosphamide alone
(200 mg/kg total over 4 days) without stem cell support was
safe and effective in producing remissions in patients with
autoimmune aplastic anemia and in a limited number of other
patients with autoimmune disease, including some with RA or
SLE [69,70]. However, in animal models, cyclophosphamide
at the highest tolerated dose produced less T-cell killing and
was less effective clinically than TBI [2,67].
There have been concerns about the risk of late-onset
malignancies from the preparatory regimens, especially TBI
regimens. Another argument against TBI, at least for MS,
includes a concern that CNS irradiation may exacerbate the
neurologic disability. In the EAE model, transient worsening
of paresis has been seen after TBI of Buffalo rats [14]. The
mechanism is unknown, but it could be related to TNF-α—a
proinﬂammatory cytokine known to be increased in active
MS [71] and shown to be induced in astrocytes and microglial
cells after even low-dose irradiation [72]. There have been
reports of a worsening of clinical inﬂammatory demyelinat-
ing polyneuropathy after transplantations in patients with
hematological malignancies who have been conditioned with
TBI [73]. Some protocols have added prednisone during
TBI conditioning [74] or cyclosporin during BEAM condi-
tioning in an attempt to modulate cytokine release [75].
There have also been concerns regarding growth retardation
with TBI in children with JIA [76] and the worsening of
skin and subcutaneous ﬁbrosis in SSc. However, neither MS
flares nor worsening of ﬁbrosis has been seen in more than
50 transplantations performed in North America, demon-
strating the safety of TBI with lung shielding in these
patients. As with any agent, dose and schedule of administra-
tion influence risks. In general, TBI-containing protocols
for autoimmunity have used doses lower (eg, 800 cGy)
than those employed in treating malignant diseases (usually
≥1200 cGy) and doses that were not associated with an
increased risk of late malignancies [77].
An analysis of EBMT registry cases showed a statistically
signiﬁcant higher transplantation-related mortality with the
higher intensity conditioning regimens (busulfan combined
with cyclophosphamide or other drugs and cyclophos-
phamide plus TBI) [78]. However, as can be seen in Figure 3,
the various preparatory regimens were not evenly distributed
across the 5 diseases shown, and differences noted in trans-
plantation-related mortality may reﬂect the disease treated
rather than the preparatory regimen used. Overall, the
choice of preparative regimens for these initial studies has
been based largely on experience, known side effects, and the
projected effects of the regimens together with the philoso-
phies of the investigators. It is unlikely that distinguishing
between regimens will be a major short-term objective of
studies in the near future, because more fundamental ques-
tions of efﬁcacy must ﬁrst be addressed.
Assessment of Clinical Results
Table 2 lists endpoints that have been used or proposed
for transplantation studies in autoimmune diseases. For MS,
potential efficacy has been evaluated by stabilization or a
decrease in disability as indicated in the EDSS scores, the
same scale used to determine eligibility. Attack frequency
has not been a useful indicator because most protocols
exclude patients with the remitting and relapsing form of
the disease. The Scripps Neurological Rating Scale (NRS)
has been used as a second indicator by some centers. NRS is
designed as a way of quantitating the standard neurological
examination [79]. Recent protocols have also included the
composite scale [80], although composite scale results for
transplantation patients have not yet been published. This
scale includes an ambulatory index, pegboard test for upper
extremity functioning, and the paced auditory serial addition
test for information processing. MRI has been used mainly
to record gadolinium enhancement as an indicator of disease
activity and T2 abnormalities, registering new lesions and
total lesion load. With one exception [75], MRIs have gen-
erally been obtained infrequently; and newer, unconven-
tional techniques to increase sensitivity and objectivity, such
as assessment of axonal loss by hypointense lesions on T1
scans (black holes), measurement of atrophy, and computer
assisted technique to measure lesion load [81,82], have not
generally been applied to transplantation patients.
SSc patients enrolled in autologous transplantation
studies have generally been treated for advanced pulmonary
disease, and high skin scores have generally been present.
The lack of previously demonstrated effective therapies for
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SSc may have limited the development of elaborate scoring
systems for quantifying responses. To date the effects of
treatment have been reported as changes in organ function
in conjunction with effects on skin scores and health assess-
ment questionnaires. Studies of organ function have generally
focused on FVC, diffusion capacity, left ventricular ejection
fraction, and pulmonary artery pressure. The mRSS is a val-
idated tool for measuring skin sclerosis [54]. It relies on phys-
ical examination, assessing 17 anatomic sites on a 0-to-3 scale
with a composite score between 0 and 51, with 0 being nor-
mal. Interobserver variability is greater than intraobserver
variability, and changes of 25% over baseline or greater in
mRSS are considered significant. Although the mRSS has
important prognostic value for survival in untreated
patients, whether changes in mRSS arising from therapy
change prognosis is uncertain. The modiﬁed health assess-
ment questionnaire disability index (mHAQ-DI) is a tool for
measuring quality of life [83]. Despite its subjective nature,
the mHAQ-DI has been shown to have prognostic value
and utility in measuring disease activity. The mHAQ and
mRSS are important secondary endpoints being used in the
currently planned prospective randomized studies of autolo-
gous transplantation for SSc.
In patients with SLE, organ-specific measurements of
function together with autoantibody titers have been used as
objective measures of disease response. Because of the
emphasis on renal disease in transplantations to date, meas-
urements of serum creatinine together with anti–double
stranded (ds)DNA have been parameters reported as show-
ing major response in SLE [84]. Although the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) [85]
has been used for determining entry into a study in some
instances, its utility has not been established for assessing dis-
ease responses. For this purpose, concern exists that the
SLEDAI overemphasizes some organ systems. More bal-
anced and potentially more useful is the BILAG (British Isles
Lupus Assessment Group) score, which appears to provide
accurate measures of current disease activity in SLE [86].
For RA, response has been documented with the American
College of Rheumatology (ACR) core set of disease activity
[87]. This instrument provides a single measure of change
based on 1 laboratory measurement (erythrocyte sedimentation
rate or C reactive protein) and 6 clinical measurements: tender
joint count, swollen joint count, patient’s assessment of pain,
patient’s and physician’s global assessment of disease activity,
and patient’s assessment of physical function. The swollen joint
and tender joint counts have been used as the main tools for
assessing disease response in initial autologous transplantation
studies of RA. These counts are used to provide a response
score, which is reported as a percentage, eg, ACR 50 or ACR
80, with the higher number indicating the greater level of
response. Early major response, eg, ACR 80, has been reported
after high-dose cyclophosphamide, indicating that considerable
reversibility of measurable disease exists for these patients.
For JIA, there is a set of core criteria similar to the ACR
core set used to evaluate changes in RA [88]. These out-
come parameters include the number of joints with swelling,
child health assessment questionnaire (CHAQ), physician’s
global assessment, limitation of range of motion, erythro-
cyte sedimentation rate, and evaluation of morning stiffness.
Complete remission was defined as a 70% or greater
improvement of at least 3 of 6 core-set criteria with, at most
1 parameter worsening [88].
RESULTS OF AUTOLOGOUS TRANSPLANTATION 
FOR AUTOIMMUNE DISEASE
Introduction
Autoimmune diseases are different, one from the other,
and it is reasonable to suppose that the best HSCT approach
for one disease may not be best for another. Patients with SLE
or SSc who are eligible for HSCT face a signiﬁcant risk of
mortality from their disease with or without transplantation,
but this is not the case for MS, RA, and JIA patients. Also,
multiple organ involvement in SLE and SSc means a greater
transplantation risk than that for the other autoimmune dis-
eases. Another obvious difference is the objectivity of inﬂam-
matory signs. Inﬂammatory signs and the effect of treatment
on these signs are directly observable in the number of
swollen painful joints in RA and JIA and skin scores in SSc.
But evaluation of an anti-inﬂammatory effect is usually indi-
rect in SLE, although measurable in organ-function tests and
even harder to track in MS. Autoimmune diseases also differ
in what is accepted as the best medical therapy, the therapy
to which HSCT ultimately will have to be compared in clini-
cal trials. Since the initiation of HSCT protocols for autoim-
Table 2. Endpoints Used or Proposed in Transplantation Studies of Autoimmune Diseases
Multiple sclerosis Extended Disability Status Scale (EDSS) [53]
Scripps Neurological Rating Scale (SNS) [79]
Composite scale [80]
Magnetic resonance imaging
Systemic sclerosis Organ function: vital capacity, pulmonary arterial pressure, diffusion capacity, cardiac ejection fraction
Modified Rodnan skin scores (mRSS) [54]
Modified health assessment questionnaire disability index (mHAQ-Di) [83]
Systemic lupus erythematosus Organ function: serum creatinine
Autoantibody titers
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [85]
British Isles Lupus Assessment Group (BILAG) scale [89]
Rheumatoid arthritis American College of Rheumatology (ACR) core set [87] 
Juvenile idiopathic arthritis Core criteria [88]
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mune diseases, there have been new therapies approved for
RA (anti-TNF drugs) and MS (mitoxantrone). There contin-
ues to be no standard therapy recognized for SSc.
Multiple Sclerosis
Mortality in 85 MS patients reported to the EBMT
registry was 8%: 2 patients died from progressive disease
and 6 from transplantation complications [6]. Two deaths
have been reported with busulfan and cyclophosphamide
conditioning, 1 from influenza pneumonia 21 days after
transplantation and 1 from pneumococcal sepsis 19 months
after transplantation [34]. With BEAM conditioning, 1 of
24 patients in the most active center died from cerebral
aspergillosis on day 65 [68]; 2 other deaths reported to the
registry from other centers occurred in the ﬁrst month from
cardiac and infectious complications, but no deaths occurred
in 23 other patients reported from the Czech Republic,
Spain, and Italy [66,75,90]. In North American reports, no
deaths in 11 patients occurred in 1 center, although 1 patient
had a traumatic CNS hemorrhage after transplantation and
was inevaluable in terms of MS neurological progression
[74], and 1 death in 26 patients treated at the other major
center occurred from Epstein-Barr virus (EBV) lymphopro-
liferative disease (attributed to rabbit ATG) [65].
Four of 23 patients who underwent mobilization of stem
cells with G-CSF alone in different centers experienced
neurological flares attributed to G-CSF [63,91]. One of
these patients, a woman with a high cervical cord demyeli-
nating lesion died after mobilization. These observations
lead to protocol modifications adding either cyclophos-
phamide (the Northwestern protocol) or prednisone (the
Seattle protocol) to the G-CSF therapy. Both of these modi-
fications appear to be effective in preventing neurological
flares. More than 85 patients in the EBMT data base [6]
have undergone mobilization with cyclophosphamide (gen-
erally 4 g/m2 or approximately 100 mg/kg) and G-CSF or
granulocyte-macrophage (GM)-CSF, and only a single MS
ﬂare has been noted [66]. Reports from the 1980s of high-
dose cyclophosphamide to treat MS (up to 100 mg/kg total
dose over 10-14 days) showed a modest benefit at best
[92,93], and there have been no MS patients enrolled on the
currently active Johns Hopkins autoimmune disease proto-
col of high-dose cyclophosphamide (200 mg/kg per day
total dose over 4 days) without HSCT [70]. However, there
is a report of a patient on an HSCT protocol from the
Czech Republic who improved 1.5 EDSS points following
mobilization with cyclophosphamide (4 g/m2) and G-CSF
and who, therefore, did not proceed with the transplantation
[66]. Furthermore, in the Italian transplantation protocol
that required MRI gadolinium enhancement for enrollment,
there was a decrease in the number of enhancing lesions
30 days after treatment with cyclophosphamide and G-CSF
for mobilization (but before high-dose immunosuppression)
in all patients, but 7 of 10 still had some gadolinium-
enhancing lesions [75]. Figure 4 shows an example of the
clearing of MRI gadolinium enhancement after cyclophos-
phamide and etoposide were administered with G-CSF for
stem cell mobilization [34].
It is difﬁcult to evaluate efﬁcacy in the presently avail-
able published clinical reports, abstracts, and registry
reports. Follow-up in most studies is still short, and MS is a
disease that is notoriously variable and hard to predict. There
is an unambiguous effect on CNS inﬂammation as seen in
MRIs. In the Italian study discussed above in which MRI
gadolinium enhancement was required for enrollment, only
2 of 10 patients had gadolinium enhancement on monthly
posttransplantation MRIs: 1 patient just in the ﬁrst month
and the other patient in each of the first 3 months post-
transplantation. It was also noted that the second patient had
new lesions on T2-weighted scans in the ﬁrst 3 months, but no
new T2 lesions were seen in the other 9 patients. The range
of follow-up scans in this study was 4 to 30 months [75].
Other trials with less frequent scans reported a similar rare
frequency of gadolinium enhancement: 2 in 24, 1 in 10, and
1 in 20 [65,68,94]. The durability of this anti-inﬂammatory
response is unknown. There has been limited neuropatho-
logical study of patients who died after transplantation
[34,95,96], but it is of interest that no active demyelination
and no T-cells in MS plaques have been seen in these cases,
including a patient who was neurologically stable when she
died of pneumococcal sepsis 19 months after transplanta-
tion. In contrast, there is generally still evidence of CNS in
situ Ig formation as shown by oligoclonal bands in the cere-
brospinal ﬂuid and an elevated CNS IgG synthesis rate after
transplantation [34,75,90].
MS symptoms characteristically are worse with temper-
ature elevation [11], and transient worsening associated with
fever has been frequently reported in the early posttrans-
plantation course [68]. The engraftment syndrome—fever,
skin rash, pulmonary inﬁltrates, and capillary leak [97,98]—
has been suspected in an unusually high number of MS
patients in the first 3 weeks after transplantation. One of
12 patients with suspected engraftment syndrome had an
EDSS progression of 1.0 point, which became permanent
during the follow-up period [65]. Another patient whose
condition worsened when G-CSF was reintroduced on day
25 improved promptly on methylprednisolone [34]. Because
of this experience, the Seattle protocol was amended to
include a prednisone course after transplantation.
Fassas has updated his clinical trial of 24 patients who were
followed for a median of 40 months (range, 21-51 months)
[68]. Patients with primary progressive MS (ie, those whose
clinical disease was progressive from onset) had limited evi-
dence of beneﬁt in that 4 of 8 progressed on the EDSS after
transplantation. The remaining 16 patients had secondary
progressive MS (ie, those whose disease becomes progres-
sive only after a remitting and relapsing course). These
patients fared considerably better; only 1 has had an EDSS
progression from pretransplantation level, and the remain-
ing have remained stable or improved. It should be noted
that of 18 patients considered to have improved, half wors-
ened on follow-up, although not beyond the pretransplanta-
tion EDSS score [68]. Primary progressive patients on the
Seattle protocol were accrued [65] but not on other single
protocol studies [34,66,74,75,90], so data are insufﬁcient to
determine the value of HSCT in primary progressive dis-
ease. A report from the Northwestern group in 2000, when
their ﬁrst 10 patients had been followed 1 to 3 years, noted
no EDSS progression and 4 patients with improved NRS
scores [74]. However, an abstract a year later noted progres-
sion by more than 0.5 EDSS points in 6 of the Northwest-
ern patients [99]. An abstract from 2000 summarizing the
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experience on the Seattle protocol reported 2 of 13 patients
followed >3 months had progressed at least 0.5 points on
the EDSS [100], and a year later 5 of 22 patients followed
>6 months had progressed at least 1.0 EDSS point [65].
With busulfan and cyclophosphamide conditioning, 1 of
4 patients in 1 study progressed at 13 months [34] and 1 of
5 in another study progressed during BCNU conditioning
[90]. European single-protocol studies with BEAM condi-
tioning showed stability or slight improvement in 10 Italian
patients in 1 study (median follow-up, 15 months; range, 4-30
months) [75] and a 1.0–EDSS point worsening at 10 months
in 1 of 9 Czech patients (median follow-up, 8.5 months;
range, 1-16 months) [66]. There is additional information in
EBMT registry reports [6], and Fassas et al. have recently
summarized the MS cases reported to the registry [101].
However, for the purpose of this review, MS outcome results
from the EBMT registry will not be presented because of the
likelihood of dual reporting of cases.
There are intrinsic difﬁculties with the EDSS that are
particularly problematic in uncontrolled trials. The EDSS is
an ordinal rather than an arithmetical scale [53]. The mean
time intervals for advancement of 1 point depend on where
the patient is on the scale. Although natural history data are
limited, particularly at the higher EDSS range, the mean
time to advance from EDSS 6.0 to 7.0 has been reported to
be almost 3.5 years [102] or just greater than 4 years [7], and
it may take even longer to advance from EDSS 7.0 to 8.0. In
contrast the mean times to advance from 4.0 to 5.0 and
5.0 to 6.0 are considerably less: 1.22 and 1.25 years, respec-
tively [103]. Furthermore, natural history studies indicate
that selection of patients at an EDSS of 6.0 or 6.5 points
who have had recent rapidly progressive disease, as has been
done in most HSCT feasibility studies, does not assure a
continual high rate of progression [102]. This is why long-
term follow-up is particularly critical in evaluating HSCT.
EDSS stabilization at 1 to 2 years of follow-up may reﬂect
the natural history of the disease rather than a therapeutic
effect of the transplantation.
In October 2000, the FDA approved mitoxantrone for
secondary progressive MS. Approval was on the basis of a
Figure 4. Magnetic resonance image of an MS patient receiving the immunosuppressive drugs cyclophosphamide and etoposide with G-CSF for
peripheral blood stem cell mobilization [34]. Upper panels (premobilization) show gadolinium enhancement and lower panels (after mobilization)
show lack of gadolinium enhancement. Both sets demonstrate “black holes” as evidence of axonal loss.
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European phase III trial of 194 patients accrued between
1993 and 1997 [104]. Details of this study at 2 and 3 years of
follow-up are on the FDA Web site (www.FDA.gov).
Entrance requirement was an EDSS score of 3 to 6 points,
lower than that for most patients who have undergone
HSCT, but within the range of what is being proposed for
future controlled trials of HSCT. Patients with primary pro-
gressive disease were excluded, whereas patients with sec-
ondary progressive disease and remitting relapsing disease
with accumulative neurological disability were included.
Treatment was given every 3 months for 2 years. At the end
of 2 years, there was 1.0 point or greater sustained EDSS
progression in 8% of patients receiving the higher mitox-
antrone dose (12 mg/m2) compared to progression in 22% of
the placebo group. This difference was sustained at 3 years
of follow-up: 17% progression in the mitoxantrone group
and 44% progression in the control group (reviewed in
[105]). Moreover, mitoxantrone has been found to be safe in
MS; no mortality and no serious cardiotoxicity was encoun-
tered even at higher doses, up to 140 mg/m2 as a total life-
time dose to avoid cardiotoxicity [106]. Whether HSCT can
do as well and whether there will be differences in durability
of the response are questions that will require a large ran-
domized trial.
Systemic Sclerosis
Among the rheumatologic disorders, more patients with
SSc have undergone HSCT than have patients with other
diseases, despite SSc being less common than RA or SLE.
This fact reﬂects the adverse prognosis of SSc, the lack of
effective alternative therapies, and the ability to deﬁne candi-
dates at risk of substantially shortened survival. To date, the
mortality risk after autologous HSCT for SSc has been
higher than that among the other autoimmune diseases. This
higher risk appears to be related to the poor underlying prog-
nosis of SSc combined with underlying organ damage that
contributes to a greater susceptibility to the toxic effects of
high-dose conditioning therapy. Initial case reports docu-
mented responses of SSc to high-dose cyclophosphamide and
HSCT [4,107], and although there have been concerns about
the toxicity, the later reports continue to show promising
results regarding disease outcomes. In a report of 41 patients
from the EBMT registry, the mortality rate in SSc patients
after transplantation was 27% (11 of 41 patients with a
median follow-up of 12 months) [56]. Four of these deaths
were attributed to disease progression, and 7 were related to
treatment (interstitial pneumonia 2, pulmonary hemorrhage
2, cardiac death 2, CNS bleed 1), including 3 patients who
died as a result of mobilization chemotherapy. Autopsy ﬁnd-
ings of an additional cardiac death in an SSc patient 2 days
after transplantation suggested cardiac involvement from SSc
and not cyclophosphamide-induced cardiomyopathy as the
cause of death [108]. The number of cardiac deaths has lead
to stricter cardiac exclusion criteria for SSc [6]. Two patients
died from regimen-related pneumonitis superimposed on SSc
pulmonary disease after receiving TBI-containing regimens,
but further instances of this toxicity were avoided with lung
shielding [64]. One patient died from EBV-associated lym-
phoproliferative disease that occurred in a recipient of rabbit
ATG [64], similar to a death that occurred in a patient with
MS [100]. Both patients received rabbit ATG because of
hypersensitivity to horse ATG. Following this experience, the
Seattle group discontinued the use of rabbit ATG in patients
with positive skin test results to horse serum.
In the registry report of 41 patients, median follow-
up was 12 months (range, 3-55 months) [56]. Although
measurements were not standardized, a beneﬁcial effect on
skin disease was reported in 69% of evaluable patients based
on their having an improvement of >25% in the baseline
skin score, whereas 7% had progression of their skin dis-
ease. Lung function and pulmonary hypertension did not
change signiﬁcantly after transplantation. Survival was 73%
at 1 year (95% conﬁdence interval, 58%-88%). Disease pro-
gression was noted in 19% of patients and occurred a
median of 67 days (range, 49-255 days) after treatment. The
improvements in skin scores and the trend toward stabiliza-
tion of lung disease were considered promising ﬁndings that
warranted further studies of this modality [56].
In the North American collaborative study, 16 patients
who received cyclophosphamide, TBI, ATG conditioning,
and CD34-selected G-CSF–mobilized autografts were
reported [64]. Three patients died of treatment complica-
tions and 1 of disease progression, indicating a survival rate
of 75%. For 6 patients with >1 year of follow-up at 1-year
posttransplantation, the mean mRSS improved from 38.2 ± 10
pretransplantation to 21.2 ± 6 (P = .002), and the mean
mHAQ-DI improved from 1.85 ± 0.9 to 0.24 ± 0.3 (P = .005);
whereas FVC and carbon monoxide diffusing capacity
(DLCO) remained stable (mean FVC [%]: 73.5 ± 6 to 74.2 ± 6,
P = .85; mean DLCO [%]: 56.5 ± 11.5 to 50.1 ± 13.5, P = .38).
In 3 patients with >2 years of follow-up, mRSS improved
from 28, 18, and 16 at 1 year to 22, 15, and 10 at 2 years,
respectively, after high-dose immunosuppressive therapy,
indicating that skin responses may continue to occur for
extended times after HSCT.
The results of initial studies have encouraged the design
of phase III studies. The European (Autologous Stem Cell
Transplantation International Scleroderma [ASTIS]) study is
a randomized study comparing conventional-dose cyclophos-
phamide with high-dose cyclophosphamide (50 mg/kg × 4).
Cyclophosphamide-mobilized (2 g/m2 × 2 + G-CSF) CD34-
selected autografts are given after high-dose cyclophos-
phamide. A similar study planned for North America will
compare cyclophosphamide, TBI, ATG conditioning, and
G-CSF–mobilized CD34-selected autografts with conven-
tional-dose cyclophosphamide (750 mg/m2 × 12). By design,
the entry criteria and control arms for the European and
North American studies are virtually identical. This design
will allow some comparison of the respective regimens for
efﬁcacy and toxicity.
Systemic Lupus Erythematosus
In the EBMT registry, mortality was 13% for 23 patients
undergoing transplantation for SLE [6]. None of 7 patients
who underwent transplantation performed by the North-
western group died, but 2 patients who underwent mobiliza-
tion for transplantation developed serious infections that
ultimately proved fatal in 1 patient and prevented both
patients from undergoing the transplantation [84]. Many of
these patients, very ill to begin with, had stormy transplan-
tation courses with ﬂuid overload and pulmonary edema a
particular problem, requiring intubation and dialysis in
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almost half of the Northwestern patients. However, once
through the acute transplantation course, there was only
mild expected morbidity with varicella zoster or herpes sim-
plex virus infection in 3 of the 7 patients and Pneumocystis
carinii pneumonia in 1 of the patients.
Of the registry patients, 19 of 23 improved, although
5 of these patients subsequently relapsed. Three patients
who underwent transplantation in Europe whose cases were
reported individually [109-111] had been in clinical remis-
sion or with improving laboratory abnormalities for up to
3 years at the time of this report. These 3 cases may be
included in the EBMT registry and are already counted in
the 19 improved SLE registry patients, referred to above. All
of the Northwestern patients have been followed for more
than 1 year, and 2 patients have been followed for more than
3 years. All 7 patients have had improvement in SLEDAI
scores, from 12 to 37 (median, 28) prior to mobilization to 0
to 5 after transplantation. There were also decreased antinu-
clear and anti-dsDNA antibody titers, decreased proteinuria,
increased FVC, normalization of representative T-helper
type 2 and T-helper type 1 cytokines, and a normalization of
T-cell repertoire after transplantation [84].
Most SLE patients in the EBMT registry received
cyclophosphamide and ATG in the preparatory regimen
(Figure 3). The Northwestern patients received cyclophos-
phamide (200 mg/kg total over 4 days, days –6 to –3) with-
out TBI or myeloablative chemotherapy, ATG on days –5 to
–3 (but not at the time of stem cell reinfusion), and CD34+
cell selection. Stem cell reinfusion on day 0 was intended to
minimize the duration of neutropenia [57]. White cell
engraftment occurred on day +9 of transplantation [84], 16
days after administration of the initial cyclophosphamide
dose. Brodsky and coworkers have used a similar regimen in
SLE but without HSCT, thus avoiding the risk of reinfusion
of autoreactive T-cells and the neutropenia associated with
cyclophosphamide/G-CSF mobilization. This regimen used
cyclophosphamide 200 mg/kg given over 4 days, without
ATG [70]. The median time to neutrophil recovery (>500
neutrophils/µL) was 17 days after the initial cyclophos-
phamide dose. Brodsky et al. have shown that the neutrophil
count generally does not fall below 500/µL until 7 to 8 days
after administration of the initial cyclophosphamide dose;
so, severe neutropenia on their protocol was only 9 to 12
days [69], a duration comparable to treatment on most
HSCT protocols. The first SLE patients treated using this
protocol had marked improvement: complete remission in 4
and partial remission in 3 [112]. Comparison trials—
cyclophosphamide with or without HSCT—will be neces-
sary to evaluate whether HSCT affects safety or efﬁcacy.
Rheumatoid Arthritis
Mortality associated with HSCT for RA has been low
compared to that for SSc and SLE. Seventy patients with RA
have been reported to the EBMT registry, and there are ade-
quate follow-up data for 43 patients [6]. Of these 43, 1 patient
(2%) died of HSCT-related complications. This low mortal-
ity rate may have been because of the less intensive immuno-
suppressive regimen in RA compared to that in MS or SSc as
well as the relative sparing of vital internal organs in RA com-
pared to that in SSc or SLE. Fourteen patients were
described as stable (1 patient) or better (13 patients).
Although most patients responded to treatment, relapses
occurred in at least 50%. The criteria for assessing improve-
ment were not deﬁned by the report.
More details are provided in individual published
reports of pilot studies than in current summaries of registry
data. Mobilization was safe and efficacious with G-CSF
alone [113]. Transient ﬂares of RA were seen in 3 patients.
Flares may be prevented with the preadministration of cor-
ticosteroids, but this combination has been investigated in
only a small number of patients [114]. Other studies have
included cyclophosphamide with G-CSF for mobilization to
prevent flares and to enhance the collection of stem cells
[60,115]. If corticosteroids are effective in preventing ﬂares,
their use would be preferable to avoid the risk of chemo-
therapy-induced neutropenia at mobilization.
A total of 25 RA patients treated with autologous
HSCT have been described in 4 reports [58-60,115]. The
high-dose immunosuppressive therapy before SCT con-
sisted of cyclophosphamide (200 mg/kg) in 20 patients,
cyclophosphamide (100 mg/kg) in 4 patients, and the com-
bination of busulfan/cyclophosphamide in 1 patient. ATG
was administered to 4 patients. High-dose chemotherapy
was well tolerated with no mortality in these published
reports. The median period of neutropenia was 10 and
11 days in the 2 studies in which it was reported. Signiﬁcant
responses were observed in 10 of 20 of the evaluable
patients receiving cyclophosphamide (200 mg/kg), and these
responses were sustained from 6 to 20 months after HSCT.
Many of the 10 patients with significant responses after
HSCT remained on lower doses of disease-modifying
antirheumatoid drugs (DMARDs) or were considered to be
more responsive to DMARDs when symptoms required
them to be restarted. In a follow-up of the Dutch study with
11 patients followed for a minimum of 1 year, there was a
significant reduction in the mean disease activity score
[115]. In one study, 4 patients who received cyclophos-
phamide (100 mg/kg) had only transient responses lasting
3 to 4 months [59]. A complete remission at 10 months was
described in a single patient who was treated with high-dose
busulfan and cyclophosphamide in combination [58].
HSCT with high-dose cyclophosphamide was not associ-
ated with signiﬁcant early toxicities. Patients will need to be
followed longer to assess the signiﬁcance of late complica-
tions. The studies to date would suggest that most patients
have early responses, and a subset of patients may continue to
have a clinical beneﬁt longer than 1 year after HSCT. When
the disease relapses, patients appear to be more responsive to
DMARDs. Future studies of RA patients refractory to con-
ventional therapy appears to be warranted and will need to
focus on the prevention of relapse or other post-SCT strate-
gies for the control of the inﬂammatory process.
Juvenile Idiopathic Arthritis
JIA is a relatively new diagnostic term replacing juvenile
RA and juvenile chronic arthritis [116]. N. Wulffraat and col-
leagues published a report of the ﬁrst small series of HSCT in
JIA and updated the series to 12 patients in 2000 [76,117]. A
summary of EBMT registry data prior to the 2000 Basel
meeting indicated 32 patients total were treated with almost
half the transplantations performed in the Netherlands [6];
there has been only 1 patient treated in the United States, and
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1 in Japan. Four (12.5%) of the 32 patients died. Follow-up
of the 28 surviving patients varied from 2 to 36 months.
Remissions were reported in 75% of these patients, but many
required continued low-dose steroids [6]. 
Three of the deaths after HSCT in JIA were from macro-
phage activation syndrome (MAS). MAS, also known as reac-
tive hemophagocytic lymphohistiocytosis, is a recognized but
uncommon complication of chronic rheumatic disease in
children. In a recent single-institution retrospective survey, 9
instances of MAS—2 of which were fatal from multiorgan
failure—were identiﬁed in a pediatric rheumatology unit that
enrolled and followed 140 new patients over a 20-year period
[118]. The trigger appears to be a nonspeciﬁc infection in
children with active inﬂammatory disease, most often chil-
dren with systemic-onset JIA. Typically MAS presents as an
acute illness and a decrease in white blood count, platelet
count, and erythrocyte sedimentation rate. The syndrome
typically involves persistent fever, hepatosplenomegaly, lym-
phadenopathy, and liver abnormalities with jaundice and
abnormal coagulation test results. A bone marrow showing
hemophagocytosis is diagnostic. The pathogenesis is thought
to involve a dysregulation of macrophage-lymphocyte inter-
action with proliferation of activated macrophages and a
release of proinflammatory cytokines. Treatment is with
high-dose corticosteroids and cyclosporine. The anti-TNF
agent, etanercept, has also been shown to be effective [119].
The high frequency of MAS after HSCT was unanticipated,
and certainly the presenting abnormalities of MAS can easily
be mistaken for other systemic complications following trans-
plantation. All instances of MAS after HSCT were fatal, with
death occurring as early as 18 days and as late as 5 months
after HSCT [117,120]. JIA patients who died with MAS after
HSCT had systemic infections: EBV reactivation in 1 patient
and toxoplasmosis in the other 2 [62,120]. To decrease the
risk of MAS, JIA protocols were amended to provide a slow
steroid taper after HSCT. Also to improve safety, there has
been more emphasis on control of the systemic rheumatolog-
ical disease prior to HSCT, and there has been a reduction in
the degree of T-cell depletion of the graft.
CONCLUDING COMMENTS
Problems in Rationale of HSCT for 
Autoimmune Diseases
As pointed out by Furst and other investigators [3,121],
effective HSCT for autoimmunity rests on several assump-
tions, not the least of which concerns “overcoming” the
autoimmune-prone genetics of the autologous stem cell. To
be something more than transient anti-inﬂammatory ther-
apy, the preparatory regimen must effectively ablate the
immune effectors. Target-tissue injury in these diseases is
thought not to be exclusively from T-cells but to be both
antibody and immune cell mediated [9]. Recent work in MS
pathology and pathogenesis has suggested a heterogeneity
in the disease, with antibody playing the primary role in a
subset of patients [122,123]. HSCT is more effective long
term in disrupting T-cell than B-cell function, and the
HSCT protocols in use were designed with a greater focus
on autoimmunity as a T-cell rather than a B-cell disease.
Another assumption for effective therapy is that the
environmental agents, which originally set the stage for
autoimmunity, are absent or their effect is no longer
reﬂected in the target-tissue microenvironment after trans-
plantation. However, because the environmental agents
involved have not been identiﬁed, any discussion on reexpo-
sure is highly speculative. Moreover, patients who have
received HSCT for autoimmune diseases may be expected
to have an array of exposed or altered autoantigens from tar-
get-tissue damage, not present earlier in individuals destined
to develop clinical autoimmunity, and these autoantigens
may replace environmental agents as disease triggers.
Finally, there is the assumption that target-tissue dam-
age will abate once the pathogenic immune effectors are
fully eliminated. However, this assumption has been called
into question at least in MS, for which an axonal degenera-
tive component is now recognized even in early disease
[124], and this component probably becomes the major
pathogenetic mechanism in patients who enter the progres-
sive stage of the disease. The effect of immunosuppression
on this degenerative component is uncertain.
Problems in Morbidity and Mortality
Overall transplantation-related mortality was reported as
9% in the EBMT registry and 11% in North American cases
[6]. These rates are considerably higher than the 3.4% treat-
ment-related mortality of autologous transplantations for
hematological malignancies and solid tumors reported in
community cancer centers [125]. Some of this higher mortal-
ity relates to a learning curve. Technologies used in treating
cancer patients have been applied to a new group of patients
with different underlying problems. In particular, a funda-
mental difference between SLE or SSc patients, in whom the
mortality has been highest, and cancer patients is the under-
lying organ dysfunction affecting lungs, liver, and heart.
These organ-specific abnormalities identify autoimmune
patients who qualify for HSCT, but similar laboratory
abnormalities in cancer patients may discourage enrollment
of those patients in high-dose investigational protocols.
Observations from HSCT pilot studies have prompted pro-
tocol and eligibility changes for future studies that should
reduce treatment morbidity and mortality. This review has
discussed some of these protocol modifications: shielding
lungs during radiation therapy in SSc, avoiding high-dose
rabbit ATG in patients with T-cell–depleted grafts, making
multiple treatment modiﬁcations to decrease risk of MAS in
JIA, using corticosteroids in MS patients at the time of G-CSF
mobilization and as a prophylaxis against persistent fever in
the engraftment syndrome, and other protocol modiﬁcations.
Also of particular importance in patients receiving T-cell–
depleted grafts is the appropriate timing and extent of reim-
munization against infectious agents [126].
Future Direction of Clinical Trials
As emphasized in this review, multiple centers, with
both small and large differences in approach, have con-
tributed to the early experience of HSCT in autoimmune
diseases. This participation has been advantageous in
establishing experienced centers for the second and more
rigorous stage of this work: namely, controlled trials of
HSCT versus best medical care. The diversified approach
with multiple small feasibility studies has also allowed the
assessment of safety of many treatment variations, includ-
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ing different preparatory regimens and different degrees of
T-cell depletion. Although registry data can be informative,
analysis is often confounded by missing data points, the
heterogeneity of the patient population, and variability of
treatments for the enrolled patients. Despite the fairly
large number of patients treated in pilot trials, there is no
assurance that the optimum HSCT method has been
found for any particular autoimmune disease. Also, various
comparative mechanistic studies of HSCT patients that
could possibly be helpful have not been done. Neverthe-
less, the consensus of investigators in the field is that care-
fully planned randomized studies are required to advance
the field. For some diseases, randomized phase II studies
now are being discussed, eg, comparison of high-dose non-
myeloablative therapy with and without HSCT in SLE and
possibly RA. In other instances, the time may be right for
phase III studies: eg, comparing HSCT to pulse
cyclophosphamide treatment in SSc and HSCT to mitox-
antrone treatment in MS. There is also agreement on the
importance of having assessors “blinded” to the patient’s
treatment group and appropriate early stopping rules for
these randomized studies.
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